These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 30221121)
1. Approaches for Effective Clinical Application of Stem Cell Transplantation. Attico E; Sceberras V; Pellegrini G Curr Transplant Rep; 2018; 5(3):244-250. PubMed ID: 30221121 [TBL] [Abstract][Full Text] [Related]
2. Prospects of Advanced Therapy Medicinal Products-Based Therapies in Regenerative Dentistry: Current Status, Comparison with Global Trends in Medicine, and Future Perspectives. Bakopoulou A J Endod; 2020 Sep; 46(9S):S175-S188. PubMed ID: 32950189 [TBL] [Abstract][Full Text] [Related]
3. European regulatory tools for advanced therapy medicinal products. Flory E; Reinhardt J Transfus Med Hemother; 2013 Dec; 40(6):409-12. PubMed ID: 24474890 [TBL] [Abstract][Full Text] [Related]
4. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective. Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215 [TBL] [Abstract][Full Text] [Related]
5. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States. Iglesias-Lopez C; Obach M; Vallano A; Agustí A Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292 [TBL] [Abstract][Full Text] [Related]
6. Advanced Therapy Medicinal Products for the Eye: Definitions and Regulatory Framework. López-Paniagua M; de la Mata A; Galindo S; Blázquez F; Calonge M; Nieto-Miguel T Pharmaceutics; 2021 Mar; 13(3):. PubMed ID: 33800934 [TBL] [Abstract][Full Text] [Related]
7. The Current State of Advanced Therapy Medicinal Products in the Czech Republic. Kočí Z; Boráň T; Krůpa P; Kubinová Š Hum Gene Ther Clin Dev; 2018 Sep; 29(3):132-147. PubMed ID: 29869533 [TBL] [Abstract][Full Text] [Related]
8. Hurdles in clinical implementation of academic advanced therapy medicinal products: A national evaluation. de Wilde S; Veltrop-Duits L; Hoozemans-Strik M; Ras T; Blom-Veenman J; Guchelaar HJ; Zandvliet M; Meij P Cytotherapy; 2016 Jun; 18(6):797-805. PubMed ID: 27068764 [TBL] [Abstract][Full Text] [Related]
9. Advanced Therapy Medicinal Products Challenges and Perspectives in Regenerative Medicine. Goula A; Gkioka V; Michalopoulos E; Katsimpoulas M; Noutsias M; Sarri EF; Stavropoulos C; Kostakis A J Clin Med Res; 2020 Dec; 12(12):780-786. PubMed ID: 33447311 [TBL] [Abstract][Full Text] [Related]
10. Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe. Farkas AM; Mariz S; Stoyanova-Beninska V; Celis P; Vamvakas S; Larsson K; Sepodes B Front Med (Lausanne); 2017; 4():53. PubMed ID: 28560211 [TBL] [Abstract][Full Text] [Related]
11. Risk of discontinuation of Advanced Therapy Medicinal Products clinical trials. Hanna E; Rémuzat C; Auquier P; Toumi M J Mark Access Health Policy; 2016; 4():. PubMed ID: 27570614 [TBL] [Abstract][Full Text] [Related]
12. Advanced therapy medicinal products: current and future perspectives. Hanna E; Rémuzat C; Auquier P; Toumi M J Mark Access Health Policy; 2016; 4():. PubMed ID: 27123193 [TBL] [Abstract][Full Text] [Related]
13. Call for More Effective Regulation of Clinical Trials with Advanced Therapy Medicinal Products Consisting of or Containing Genetically Modified Organisms in the European Union. Beattie S; Hum Gene Ther; 2021 Oct; 32(19-20):997-1003. PubMed ID: 33843251 [TBL] [Abstract][Full Text] [Related]
14. Advanced Therapy Medicinal Products: How to Bring Cell-Based Medicinal Products Successfully to the Market - Report from the CAT-DGTI-GSCN Workshop at the DGTI Annual Meeting 2014. Celis P; Ferry N; Hystad M; Schüßler-Lenz M; Doevendans PA; Flory E; Beuneu C; Reischl I; Salmikangas P Transfus Med Hemother; 2015 May; 42(3):194-9. PubMed ID: 26195933 [TBL] [Abstract][Full Text] [Related]
15. Cell therapy medicinal product regulatory framework in Europe and its application for MSC-based therapy development. Ancans J Front Immunol; 2012; 3():253. PubMed ID: 22912639 [TBL] [Abstract][Full Text] [Related]
16. [Scientific advice by the national and European approval authorities concerning advanced therapy medicinal products]. Jost N; Schüssler-Lenz M; Ziegele B; Reinhardt J Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1207-14. PubMed ID: 26369763 [TBL] [Abstract][Full Text] [Related]
17. Evolution of Mesenchymal Stem Cell Therapy as an Advanced Therapeutic Medicinal Product (ATMP)-An Indian Perspective. Muthu S; Jeyaraman M; Kotner MB; Jeyaraman N; Rajendran RL; Sharma S; Khanna M; Rajendran SNS; Oh JM; Gangadaran P; Ahn BC Bioengineering (Basel); 2022 Mar; 9(3):. PubMed ID: 35324800 [TBL] [Abstract][Full Text] [Related]
18. Beyond the Present Constraints That Prevent a Wide Spread of Tissue Engineering and Regenerative Medicine Approaches. O'Donnell BT; Ives CJ; Mohiuddin OA; Bunnell BA Front Bioeng Biotechnol; 2019; 7():95. PubMed ID: 31134194 [TBL] [Abstract][Full Text] [Related]
19. The future of Cochrane Neonatal. Soll RF; Ovelman C; McGuire W Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834 [TBL] [Abstract][Full Text] [Related]
20. [European Marketing Authorisation: a long process. Experiences of small biotech companies with the ATMP regulation]. Buljovčić Z Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):831-8. PubMed ID: 21698536 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]